ID: ALA2180803

Max Phase: Preclinical

Molecular Formula: C21H20N6O2

Molecular Weight: 388.43

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1ccc2[nH]c(Nc3ccc(Oc4nccnc4N4CCOCC4)cc3)nc2c1

Standard InChI:  InChI=1S/C21H20N6O2/c1-2-4-18-17(3-1)25-21(26-18)24-15-5-7-16(8-6-15)29-20-19(22-9-10-23-20)27-11-13-28-14-12-27/h1-10H,11-14H2,(H2,24,25,26)

Standard InChI Key:  AYQCPWIILRLNBK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 388.43

Molecular Weight (Monoisotopic): 388.1648

AlogP: 3.73

#Rotatable Bonds: 5

Polar Surface Area: 88.19

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.85

CX Basic pKa: 7.40

CX LogP: 3.53

CX LogD: 3.24

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.54

Np Likeness Score: -1.62

References

1. Chappie TA, Helal CJ, Hou X..  (2012)  Current landscape of phosphodiesterase 10A (PDE10A) inhibition.,  55  (17): [PMID:22834877] [10.1021/jm3004976]

2. Hu E, Kunz RK, Chen N, Rumfelt S, Siegmund A, Andrews K, Chmait S, Zhao S, Davis C, Chen H, Lester-Zeiner D, Ma J, Biorn C, Shi J, Porter A, Treanor J, Allen JR..  (2013)  Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A).,  56  (21): [PMID:24102193] [10.1021/jm401234w]

Source

Source(1):

• Scientific Literature